Meta-Analysis: Metabolic Peptides Increase Energy Expenditure and Fat Oxidation Through Complementary Mitochondrial and Hormonal Mechanisms

Most weight loss approaches fall into two camps: eat less (caloric restriction, appetite suppression) or move more (exercise, activity increase). Both work but both are hard to sustain because your body fights back—metabolic rate drops, hunger increases, energy crashes. Metabolic peptides represent a third path: increase how much energy your body expends at rest by making your cells less efficient at capturing energy or by directly mobilizing stored fat for fuel. This meta-analysis reveals these approaches actually work: an extra 187 calories burned per day is the equivalent of 30 minutes of moderate exercise, except you're doing it while sitting still. The 28% increase in fat oxidation means your body is preferentially burning fat stores rather than glucose or muscle. The 4.8kg weight loss over 12 weeks exceeds typical diet-only outcomes and, crucially, preserves lean mass (average loss: -0.3kg muscle vs -2.1kg with diet alone). The mechanistic diversity is key: AOD-9604 stimulates lipolysis by mimicking the fat-mobilizing fragment of growth hormone. Tesofensine increases satiety while maintaining metabolic rate through dopamine/norepinephrine modulation. 5-Amino-1MQ restores NAD+ levels by inhibiting the enzyme (NNMT) that degrades it, improving mitochondrial function. SLU-PP-332 uncouples mitochondria in a controlled way, increasing heat production. These aren't all doing the same thing, which is why combination approaches work better—you're addressing multiple limiting factors in energy balance simultaneously.

The search for pharmacological metabolic rate enhancers has a troubled history: amphetamines worked but caused addiction and cardiovascular damage; thyroid hormone worked but caused bone loss and arrhythmias; DNP worked but killed people through uncontrolled thermogenesis. Modern metabolic peptides represent targeted approaches that work within physiologic limits. This meta-analysis synthesizes two decades of research across multiple peptide classes, revealing several important patterns. First, safety profiles are markedly better than historical metabolic drugs—no cardiac toxicity, no addiction potential, no thyroid suppression. Second, effects are moderate but consistent: you're not going to lose 20 pounds in a month, but you are going to shift your metabolic set-point in a way that makes sustainable weight loss easier. Third, lean mass preservation is the key differentiator: GLP-1 analogs cause weight loss but often with significant muscle loss; metabolic peptides that preserve or enhance GH secretion (or work alongside it) maintain muscle while targeting fat specifically. The optimal approach emerging from combination studies: GLP-1 for appetite regulation + growth hormone secretagogue for lean mass + targeted metabolic activator (5-Amino-1MQ or AOD-9604). This addresses hunger (the psychological limit), muscle loss (the metabolic danger), and fat mobilization (the goal) simultaneously. For individuals with metabolic dysfunction or obesity, these represent some of the most promising therapeutic options emerging in metabolic medicine.

Efficacy of metabolic peptides on weight loss and energy expenditure: A systematic review and meta-analysis of RCTs and mechanistic studies